-+ 0.00%
-+ 0.00%
-+ 0.00%

Five new products of Luye Pharmaceutical (02186) were successfully included in the 2025 National Medical Insurance Drug Catalogue or Commercial Insurance Innovative Drug Catalogue

Zhitongcaijing·12/07/2025 10:49:03
Listen to the news

Zhitong Finance App News, Luye Pharmaceutical (02186) announced that five new products of the Group were successfully included in the “National Catalogue of Drugs for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance (2025)” (National Medical Insurance Drug Catalogue) or “Commercial Health Insurance Innovative Drug Catalogue (2025)” (Commercial Insurance Innovative Drug Catalogue) issued by the National Medical Security Administration.

The five new products include: Mimexin® (oxycodone naloxone extended-release tablets) and Revalide® (paliperidone palmitate injection (II)) was included in the national medical insurance drug catalogue for the first time; Zanbijia® (injectable rubitidine) was successfully selected in the commercial insurance innovative drug catalogue; Piotowei® (injectable goserelin microspheres) and Ricotalol® (injectable risperidone microspheres (Ⅱ)) were successfully renewed and continued to be included in the national medical insurance drug catalogue.